| Autor: |
Barna AJ; Department of Obstetrics and Gynecology, Saint Pantaleon Hospital, H-2400 Dunaujvaros, Hungary.; Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary., Herold Z; Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary., Acs M; Department of Surgery, University Hospital, D-93053 Regensburg, Germany., Bazsa S; Department of Obstetrics and Gynecology, Saint Pantaleon Hospital, H-2400 Dunaujvaros, Hungary., Gajdacsi J; Directorate General of Medical Quality Assurance, Semmelweis University, H-1085 Budapest, Hungary., Garay TM; Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary.; Faculty of Information Technology and Bionics, Pazmany Peter Catholic University, H-1083 Budapest, Hungary., Herold M; Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary.; Department of Internal Medicine and Hematology, Semmelweis University, H-1088 Budapest, Hungary., Madaras L; Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H-1091 Budapest, Hungary., Muhl D; Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary., Nagy A; Department of Pathology and Experimental Cancer Research, Semmelweis University, H-1085 Budapest, Hungary., Szasz AM; Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary., Dank M; Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary. |
| Abstrakt: |
Cancer-related immunity plays a significant role in the outcome of ovarian cancer, but the exact mechanisms are not fully explored. A retrospective, real-life observational study was conducted including 57 advanced ovarian cancer patients. Immunohistochemistry for CD4 + , CD8 + , and CD45 + was used for assessing tumor-infiltrating immune cells. Furthermore, an immune-related gene expression assay was performed on 12-10 samples from patients with less than and more than 1-year overall survival (OS), respectively. A higher number of CD4 + ( p = 0.0028) and CD45 + ( p = 0.0221) immune cells within the tumor microenvironment were associated with longer OS of patients. In a multivariate setting, higher CD4 + T cell infiltration predicted longer OS ( p = 0.0392). Twenty-three differentially expressed genes-involved in antigen presentation, costimulatory signaling, matrix remodeling, metastasis formation, and myeloid cell activity-were found when comparing the prognostic groups. It was found that tumor-infiltrating immune cell counts are associated with peculiar gene expression patterns and bear prognostic information in ovarian cancer. SOX11 expression emerged and was validated as a predictive marker for OS. |
